Figure 2.
Objective response rate (ORR) and disease control rate (DCR) of TAS-102 monotherapy or combination therapy with bevacizumab for metastatic colorectal cancer.
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.